Core Insights - The presentation outlines four strategic priorities referred to as "must-win battles" for the company [2] Group 1: Strategic Priorities - The first priority is to "Simplify, Empower and Speed," which includes the establishment of a new operating model that is expected to generate SEK 500 million in annual savings [2] - The second priority focuses on "focused innovation" to enhance product offerings [2] - The third priority aims to "win in the U.S. and expand in China," indicating a strategic push in these key markets [2] - The fourth priority is centered on "continuous COGS reduction," which aims to improve cost efficiency [2] Group 2: Presentation Details - The presentation does not include any new financial data, focusing instead on strategic initiatives [3]

Conmed (CNMD) reported $373.2 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 7.9%. EPS of $1.43 for the same period compares to $1.34 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $366.22 million, representing a surprise of +1.91%. The company delivered an EPS surprise of +8.61%, with the consensus EPS estimate being $1.32.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Stre ...

Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statements in this press release when it discusses: the proposed inclusion of cryoablation in medical society treatment guidelines; the expected impact of such inclusion on physician adoption, patient access, reimbursement coverage, and commercial adoption of ProSense ...

SALT LAKE CITY--(BUSINESS WIRE)--Varex Imaging Corporation (Nasdaq: VREX) today announced that it will report unaudited financial results for the first quarter of fiscal year 2026, following the close of regular trading on Tuesday, February 10, 2026. The earnings news release will be followed by a conference call at 3:00 pm Mountain Time that day. This call will be webcast live and can be accessed at the company's website at www.vareximaging.com/investor-relations/. Investors can also access this conference ...

Louvain-La-Neuve, Belgium, January 27, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed a contract for the supply of a Proteus®ONE1 compact proton therapy solution to be installed at the MacKay Memorial Hospital in New Taipei City, Taiwan. This is the fourth order of a Proteus®ONE system in Taiwan, further reinforcing IBA’s position as ...

Core Insights - Jin Medical International Ltd. will host a fireside chat on February 1, 2026, to discuss its strategic priorities and long-term growth considerations [1] - The company has launched an updated corporate website where the fireside chat will be webcast [2] Company Overview - Jin Medical, founded in 2006 and headquartered in Changzhou, Jiangsu Province, China, specializes in designing, developing, manufacturing, and marketing rehabilitation medical equipment, including wheelchairs and living aids [3] - The company operates two manufacturing plants totaling approximately 230,000 square feet in Changzhou and Taizhou, and is establishing a new facility of 430,000 square feet in Chuzhou, Anhui Province [3] - Jin Medical collaborates with over 40 distributors in China and more than 20 international distributors, with a significant portion of its wheelchair products sold to Japan and China [3] - The company offers more than 30 models of lightweight and ergonomic wheelchairs [3]

Core Viewpoint - The upcoming 4Q/FY25 results for NVST are anticipated to exceed analysts' conservative forecasts, potentially leading to a re-rating of its shares [1]. Group 1: Company Overview - NVST is set to release its financial results next week, which is a significant event for investors [1]. - The analysis suggests that the current market expectations for NVST's earnings are overly cautious [1]. Group 2: Investment Strategy - The focus is on identifying Asia-listed stocks that exhibit a substantial gap between their market price and intrinsic value, particularly in the context of deep value balance sheet bargains and wide moat stocks [1][2]. - The investment strategy includes targeting stocks that are undervalued based on metrics such as net cash, low price-to-book ratios, and sum-of-the-parts discounts [1].

Ahead of today’s opening bell, Thursday morning Weekly Jobless Claims are out, and they continue to portray a labor market cruising along at a healthy low rate of unemployment claims. Initial Jobless Claims came in at an even +200K, 8K below expectations and a tick up from the slightly upwardly revised +199K the previous week. Our trailing four-week average on new jobless claims is now +202K, -15K lower per week than the previous four weeks.Continuing Claims, reported a week in arrears from new claims, reac ...

Core Viewpoint - Jin Medical International Ltd. is advancing its manufacturing capabilities with the construction of a new facility in Chuzhou, Anhui Province, expected to enhance production of mid-to-high-end electric wheelchairs and senior mobility scooters, aligning with the growing global demand for assistive devices driven by aging populations [1][4]. Company Developments - The Chuzhou facility is projected to achieve full production capacity by the end of April 2026, with an annual output capacity of 200,000 units [1]. - The facility has received regulatory approval for Class I Medical Device production, completing necessary filings with local authorities on December 29, 2025 [1]. - The new facility will utilize automated production lines to improve cost control and product quality consistency [3]. Strategic Importance - The Chuzhou facility is strategically located in the Yangtze River Delta's manufacturing hub, providing geographical and supply chain advantages [2]. - The project is expected to significantly enhance Jin Medical's manufacturing capabilities in premium mobility products, thereby improving market competitiveness [4]. - The completion of this project supports the company's strategic goal of optimizing global production capacities and enhancing supply chain resilience [3]. Industry Context - The expansion of Jin Medical coincides with a growing global demand for assistive devices, driven by the aging trend [4]. - The facility's efficient scaled production is anticipated to create sustained value for shareholders through effective execution of the project [4]. Company Background - Jin Medical, founded in 2006, designs, develops, manufactures, and markets wheelchairs and living aids for people with disabilities and the elderly [5]. - The company currently operates two manufacturing plants totaling approximately 230,000 square feet and is establishing a new facility of 430,000 square feet in Chuzhou [5]. - Jin Medical collaborates with over 40 distributors in China and more than 20 international distributors, with a significant portion of its products sold in Japan and China [5].

Changzhou, China, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Jin Medical International Ltd. (NASDAQ: ZJYL) (“Jin Medical”, and together with all its subsidiaries, the ”Company”), a NASDAQ-listed leading provider of rehabilitation medical equipment in China, announced today that members of its management team will host a fireside chat on February 1, 2026, to provide an update on the Company’s strategic priorities and capital structure considerations. During the discussion, the management team will address recent mark ...